# Merit Medical Systems, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Merit Medical Systems, Inc). ## Overview Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures. Its portfolio is concentrated in cardiology, radiology, oncology, critical care, and endoscopy, with sales split between the United States and international markets. ## Products & services • Interventional cardiology and radiology devices • Neurointerventional and vascular access products • Endoscopy and interventional gastroenterology devices • Oncology, pain management, and breast cancer surgery products • Critical care, imaging, and intensive care devices - **Cardiology and radiology access devices** (40%) — Catheters, syringes, access systems, and related devices used in diagnostic and interventional procedures. - **Endoscopy and gastroenterology** (15%) — Devices used in endoscopic and interventional GI procedures, including acquired products such as EsophyX. - **Oncology and specialty therapy products** (15%) — Products used in interventional oncology, pain management, breast cancer surgery, and related procedures. - **Critical care and intensive care** (15%) — Devices supporting ICU, imaging, and other hospital-based care settings. - **Other interventional and OEM products** (15%) — Ancillary products and OEM offerings sold through direct and partner channels. - Interventional cardiology and radiology devices - Neurointerventional and vascular access products - Endoscopy and interventional gastroenterology devices - Oncology, pain management, and breast cancer surgery products - Critical care, imaging, and intensive care devices ## Customers Merit sells primarily to hospitals, ambulatory and outpatient access centers, and physician-led procedural departments that need disposable and procedure-specific devices. Its customers buy for clinical performance, reliability, breadth of line, and supply continuity in high-volume interventional workflows. - **Hospitals and integrated delivery networks** (primary) — Buy interventional, critical care, and imaging devices for inpatient and procedural use where reliability and breadth of line matter. - **Cath lab, radiology, and oncology departments** (primary) — Purchase access, catheter, and procedure devices for cardiology, radiology, and oncology interventions. - **Endoscopy and GI centers** (secondary) — Buy endoscopy-related products, including acquired offerings, for therapeutic and diagnostic procedures. - **Outpatient access centers** (secondary) — Use Merit devices for outpatient procedures that require sterile, single-use access and intervention products. - **OEM and channel partners** (secondary) — Purchase products for incorporation into broader offerings or for distribution in specific geographies. - Hospitals and health systems buying devices for interventional procedures - Cath labs and radiology departments needing procedure-specific access tools - Endoscopy and GI centers using devices for therapeutic procedures - Outpatient access centers and ambulatory sites seeking disposable devices - OEM and distributor customers purchasing Merit products for resale or integration ## Geography Merit generated 60.0% of 2025 revenue in the United States and 40.0% internationally, so the business is meaningfully exposed to both domestic procedure volumes and foreign currency movements. International growth was driven mainly by EMEA, with additional contribution from Rest of World and Asia Pacific, making regional reimbursement, trade policy, and local competition important to performance. - **United States** (60%) — 2025 annual sales - **International** (40%) — 2025 annual sales; includes EMEA, APAC, and ROW - United States accounted for 60.0% of 2025 sales - International markets accounted for 40.0% of 2025 sales - EMEA was the largest international growth driver in 2025 - Asia Pacific and Rest of World also contributed to international growth - Foreign currency movements affect reported international sales ## Strategy Merit’s strategy centers on growing through R&D, sales model optimization, cost discipline, and operational focus while targeting high-return opportunities in core divisions. Management also emphasizes lean manufacturing, asset utilization, and acquisitions that expand the portfolio, such as Cook Medical and EndoGastric Solutions. - **Expand core product innovation** (medium-term) — New and improved devices support pricing power, customer retention, and share gains in competitive procedural markets. - **Integrate recent acquisitions** (short-term) — Cook Medical and EndoGastric Solutions should broaden the portfolio and add revenue, but only if integration and commercialization succeed. - **Improve operational efficiency** (medium-term) — Lean manufacturing and cost discipline are needed to protect margins in a price-competitive, regulated device market. - Grow through R&D and product innovation in core clinical areas - Optimize the sales model to improve reach and profitability - Use lean processes and asset utilization to lower operating cost - Pursue acquisitions that add products and expand end markets - Maintain a customer-focused model to defend share and pricing ## Risks Merit faces execution risk from acquisitions, supply chain and sterilization disruptions, and the challenge of integrating new products into its commercial and IT systems. As a medical device company, it is also exposed to regulatory clearance, product liability, reimbursement pressure, cybersecurity, and foreign exchange volatility, all of which can affect revenue, margins, and compliance costs. - **Acquisition integration risk** [high] — Recent deals must be integrated commercially, operationally, and in IT systems to realize expected benefits. - **Supply chain and sterilization disruption** [high] — Merit relies on third-party vendors and manufacturing/sterilization processes to deliver products on time. - **Regulatory and compliance risk** [high] — Medical devices require clearance, approval, and ongoing compliance in multiple jurisdictions. - **Cybersecurity and data integrity risk** [medium] — System breaches or disruptions could affect operations, customer trust, and regulatory obligations. - **Foreign exchange and trade policy risk** [medium] — International sales and sourcing expose the company to currency swings, tariffs, and cross-border policy changes. - Acquisition integration may fail to deliver expected revenue or cost synergies - Supply chain or sterilization disruptions can interrupt product availability - Regulatory approvals and product maintenance are required to keep products on market - Cybersecurity incidents could disrupt systems or expose sensitive data - Foreign exchange, tariffs, and reimbursement changes can pressure results ## Accounting The most important accounting judgments are goodwill and intangible asset impairment testing, especially after acquisitions, because future cash flow assumptions can materially affect reported asset values. Investors should also watch revenue seasonality and geographic mix, since U.S. and international sales move differently, and acquisition accounting can add amortization and contingent consideration effects. - **Goodwill and intangible asset impairment** — Could create non-cash charges if acquired businesses underperform - **Acquisition accounting and amortization** — Impacts comparability of margins and earnings across periods - **Foreign currency translation** — Affects reported international sales and margin trends - **Revenue seasonality and procedure timing** — Affects quarter-to-quarter comparability - Goodwill and intangible asset impairment depends on cash flow and discount rate assumptions - Acquisition accounting can increase amortization and affect comparability - Revenue mix by geography can shift reported growth because of FX and regional demand - Contingent consideration and acquisition-related liabilities may affect earnings - Quarterly sales can vary with procedure volumes and acquired product timing --- *Last updated: 2026-04-28T20:24:51.955032+00:00*